Navigation Links
New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

WAYNE, N.J. and EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of new clinical data from the early clinical trials in the development program for Nexavar(R) (sorafenib) tablets in multiple tumor types including lung, thyroid, gastric and ovarian cancers. Nexavar is currently approved in more than 40 countries for the treatment of patients with unresectable liver cancer and in more than 70 countries for the treatment of patients with advanced kidney cancer.

"Findings from these early phase studies are encouraging and will be integral in informing our development strategies for the ongoing Nexavar clinical program," said Henry Fuchs, MD, executive vice president and chief medical officer of Onyx Pharmaceuticals. "We are committed to maximizing the potential of Nexavar and look forward to its ongoing study with international study groups, government agencies and individual investigators in a wide range of cancers."

Highlights from Nexavar data presented include:

Lung Cancer

A Randomized, Discontinuation Phase 2 Study of Sorafenib vs. Placebo in Patients with Non-Small Cell Lung Cancer (NSCLC) Who Have Failed at Least Two Prior Chemotherapy Regimens

Preliminary findings from this randomized discontinuation Phase 2 study showed that treatment with Nexavar yielded encouraging results in heavily pre-treated patients with NSCLC. The study showed that patients who remained on Nexavar experienced a longer period of disease control and disease stabilization than patients who discontinued Nexavar after the initial run-in phase of treatment. In the study, the most common treatment-emergent adver
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
2. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
3. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
10. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 InfinityQS International, Inc., the global ... , today announces Infusion Chicago, its 9 th ... held Oct. 9-10, 2014, at the Chicago Marriott ... the necessity for implementing a quality system that ... to gain insight into production processes. Complimentary registrations ...
(Date:8/21/2014)... , Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... applicable Reference Yields and consideration payable in connection with its ... August 7, 2014 for (1) any and all of its ... and (2) up to a maximum amount of its 6.125% ... 5.750% Senior Notes due 2017 (collectively, the "Maximum Tender Offer ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis ... three independent members to its Board of Directors, ... experience of the company, a leading licensed producer ... . Internationally, Bedrocan has 13 years, experience in ... in seven countries, including Canada. ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3
... REGENSBURG, Germany, June 2 The TGF-beta 2,inhibitor ... good safety,and tolerability in the systemic treatment of ... administered,intravenously, showed a clear proof of concept. Patients ... for seven days every other week,as second or ...
... Transplant Congress in Toronto, MIAMI, June 2 ... Departments of Surgery and Pathology at the University ... corroborated the value of,monitoring cell- mediated immunity (CMI) ... regular laboratory assay of cell function,(ImmuKnow(R)/Cylex). Their paper, ...
Cached Medicine Technology:Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 2Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 3Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 4University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 2University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 3University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 4
(Date:8/21/2014)... 21, 2014 DMG Productions announces the ... to broadcast on Monday, August 25, 2014 at 7:00 ... , In this episode, Innovations will go behind-the-scenes ... and improves human performance. Audiences will be amazed by ... spaces by installing and providing access to real musical ...
(Date:8/21/2014)... Raleigh, NC (PRWEB) August 21, 2014 ... proteins produced by Staph bacteria has been used to ... just posted an article on the new research. ... at the University of Western Australia treated mesothelioma ... that it killed the cancer cells while simultaneously stimulating ...
(Date:8/21/2014)... San Luis Obispo, CA (PRWEB) August 21, 2014 ... July/August edition of Current Pedorthics, a bi-monthly publication of the ... the field of pedorthics. , Bunion Bootie ... as an alternative solution for bunion sufferers and their pain. ... be worn in nearly any shoe to eliminate the friction ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to a ... Academy of Ophthalmology, environmental factors may outweigh genetics in the ... 42 percent of the world’s population is nearsighted, and this ... , “This is an important finding in the field ... “Not only are we finding better ways to treat ...
(Date:8/21/2014)... Beverly Hills Medical Center of Kuwait is excited to ... a new diagnostic option for measuring tear production levels to ... TearLab is a revolutionary new testing method for dry ... amount of tears a patient produces and take the necessary ... Director at the Kuwait medical center. “The test collects a ...
Breaking Medicine News(10 mins):Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Beverly Hills Kuwait is the First Medical Center in Kuwait with Access to TearLab 2
... ON, Sept. 17 /PRNewswire-FirstCall/ - AlphaRx Inc. ... to developing the next,generation of therapeutic products ... candidate, Streptomycin nanoparticles,will be the subject of ... in,Treatment and Pathogenesis of Mycobacterial Infections" at ...
... Company Serves as a Free Resource to Employees Seeking Senior ... ... the nation,s largest,referral service of senior care options, was recently recognized in ... to when an,employer does not offer eldercare assistance as a part of ...
... genes can work in more powerful and sneaky ways than ... JAK that is closely related to a common cancer-causing gene ... manner. JAK disrupts the activity of an organisms DNA on ... on in an embryos development. , A team from the ...
... Hotel, Washington, D.C.,National and International Health Care Professionals will Convene to ... ... Failure Patients, WASHINGTON, Sept. 17 ... convenes Sunday, September,16, 2007 at the Marriott Wardman Park Hotel in ...
... out of 4 Slept Better on New Sleep Better(TM) ... effort to test the,connection between a new, quality bed ... townspeople of Pillow, Pa. let go of one of ... Sleep Better(TM),Project. Residents of this central Pennsylvania bedroom ...
... 16, 2007 New findings by UT Southwestern Medical ... interferes with the beneficial effects estrogen has on the ... between cholesterol and estrogen in heart disease. , The ... October issue of the journal Nature Medicine , ...
Cached Medicine News:Health News:AlphaRx To Present at 47th Annual ICAAC 2Health News:A Place for Mom, Nation's Largest Senior Care Referral Service, Fills a Gap in Employee Benefits 2Health News:If you think cancer genes are simple, you don't know JAK 2Health News:If you think cancer genes are simple, you don't know JAK 3Health News:If you think cancer genes are simple, you don't know JAK 4Health News:If you think cancer genes are simple, you don't know JAK 5Health News:Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research 2Health News:Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research 3Health News:Pillow, PA's Great American Sleep Better(TM)Project Reports Results 2Health News:Pillow, PA's Great American Sleep Better(TM)Project Reports Results 3Health News:Cholesterol byproduct blocks heart health benefits of estrogen 2Health News:Cholesterol byproduct blocks heart health benefits of estrogen 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: